<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ghada El-Hajj Fuleihan, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shonni J Silverberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The diagnosis of hyperparathyroidism is usually first suspected because of the finding of an elevated serum calcium concentration. If hypercalcemia is confirmed on a repeat sample, all potential causes should be considered  (<a class="graphic graphic_table graphicRef66865" href="/z/d/graphic/66865.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a>.)</p><p>The serum parathyroid hormone (PTH) concentration should then be measured using a two-site immunoradiometric sandwich assay. The diagnosis of primary hyperparathyroidism (PHPT) is usually made by finding a PTH concentration that is frankly elevated or within the normal range but inappropriately normal given the patient's hypercalcemia  (<a class="graphic graphic_figure graphicRef50252" href="/z/d/graphic/50252.html" rel="external">figure 1</a>).</p><p>The diagnosis, differential diagnosis, and evaluation of PHPT will be discussed here. Other aspects of PHPT are reviewed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2038.html" rel="external">"Primary hyperparathyroidism: Pathogenesis and etiology"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary hyperparathyroidism (PHPT)</strong> – In countries where biochemical screening is performed, the most common clinical presentation of PHPT is asymptomatic hypercalcemia. The diagnosis is usually first suspected because of the incidental finding of an elevated serum calcium concentration on routine screening tests. In addition, PHPT may be suspected in a patient with nephrolithiasis. If hypercalcemia is confirmed, intact parathyroid hormone (PTH) should be measured concomitantly with the serum calcium.</p><p></p><p class="bulletIndent1">PHPT is diagnosed by finding a frankly elevated PTH concentration in a patient with hypercalcemia. Findings must be evident on two occasions at least two weeks apart [<a href="#rid1">1</a>]. When the PTH is only minimally elevated or within the normal range (but inappropriately normal given the patient's hypercalcemia), PHPT remains the most likely diagnosis, although familial hypocalciuric hypercalcemia (FHH)  (<a class="graphic graphic_figure graphicRef50252" href="/z/d/graphic/50252.html" rel="external">figure 1</a> and <a class="graphic graphic_algorithm graphicRef138634" href="/z/d/graphic/138634.html" rel="external">algorithm 1</a>) is possible [<a href="#rid2">2</a>]. (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normocalcemic PHPT</strong> – Normocalcemic PHPT is a variant of PHPT [<a href="#rid1">1</a>]. Patients with normocalcemic PHPT typically come to medical attention in the setting of an evaluation for low bone mineral density (BMD), during which PTH levels are drawn and found to be elevated in the absence of hypercalcemia [<a href="#rid3">3-6</a>]. In order to make a diagnosis of normocalcemic PHPT, total calcium (adjusted for albumin) and ionized calcium levels should be consistently normal in the presence of elevated levels of PTH, and all secondary causes for hyperparathyroidism  (<a class="graphic graphic_table graphicRef73157" href="/z/d/graphic/73157.html" rel="external">table 2</a>) must be ruled out [<a href="#rid1">1</a>]. Vitamin D deficiency and chronic kidney disease are the most common causes of secondary hyperparathyroidism; however, the precise serum 25-hydroxyvitamin D (25[OH]D) and estimated glomerular filtration rate (eGFR) thresholds for defining them are not well established [<a href="#rid7">7,8</a>]. Biochemical findings of normocalcemic PHPT must be evident on multiple measurements over a three- to six-month period [<a href="#rid9">9</a>]. (See <a class="local">'Secondary hyperparathyroidism'</a> below.)</p><p></p><p class="headingAnchor" id="H3563575"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H3"><span class="h2">Serum calcium</span><span class="headingEndMark"> — </span>A single elevated serum calcium concentration should be repeated to confirm the presence of hypercalcemia. The total serum calcium concentration should be used for both the initial and the repeat serum calcium measurements. If a laboratory known to measure ionized calcium reliably is available, some experts prefer to measure the ionized calcium, although this usually adds little to the diagnosis of asymptomatic primary hyperparathyroidism (PHPT) in patients with normal serum albumin concentrations and no abnormalities in acid-base balance [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia", section on 'Confirm hypercalcemia'</a>.)</p><p>One circumstance in which ionized calcium measurements are an important adjunct to diagnosis is in patients with presumed normocalcemic PHPT. In order to make this diagnosis, ionized calcium levels should be measured several times and should be consistently normal [<a href="#rid11">11</a>]. In one series, 12 of 60 patients in whom the diagnosis of normocalcemic PHPT was considered had a raised serum concentration of ionized calcium in the presence of a normal total serum calcium concentration [<a href="#rid12">12</a>].</p><p>Previous values for serum calcium should be reviewed, if available. The presence of longstanding asymptomatic hypercalcemia is more suggestive of PHPT and, in young individuals, also raises the possibility of familial hypocalciuric hypercalcemia (FHH).</p><p class="headingAnchor" id="H4"><span class="h2">Serum PTH</span><span class="headingEndMark"> — </span>Either intact parathyroid hormone (PTH; second-generation PTH assay) or PTH (1-84) (third-generation assay) should be measured concomitantly with the serum calcium level to diagnose hyperparathyroidism [<a href="#rid13">13</a>]. Although limited data [<a href="#rid14">14</a>] suggest that PTH is increased in a higher proportion of patients with PHPT using the PTH (1-84) assay, several other studies have found no increase in diagnostic utility [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2055.html" rel="external">"Parathyroid hormone assays and their clinical use", section on 'Clinical use of PTH assays'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTH elevated</strong> – Approximately 80 to 90 percent of patients with PHPT have serum PTH concentrations above the normal range for the assay  (<a class="graphic graphic_figure graphicRef50252" href="/z/d/graphic/50252.html" rel="external">figure 1</a> and <a class="graphic graphic_algorithm graphicRef138634" data-inline-graphics="138634" href="/z/d/graphic/138634.html" rel="external">algorithm 1</a>) [<a href="#rid17">17,18</a>]. In contrast to parathyroid cancer and secondary hyperparathyroidism associated with kidney failure, the extent of elevation in PHPT tends to be modest, often in the range of 1.5 to 2-fold the upper limit of normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTH within normal range</strong> – Ten to 20 percent of patients have serum PTH values that are only minimally elevated or normal [<a href="#rid19">19</a>]. These "normal" values in the presence of hypercalcemia are inappropriately high; healthy individuals given calcium intravenously have suppressed serum PTH concentrations (below 10 pg/mL), and patients with non-PTH-mediated hypercalcemia virtually always have values below 20 to 25 pg/mL  (<a class="graphic graphic_figure graphicRef50252" href="/z/d/graphic/50252.html" rel="external">figure 1</a>) [<a href="#rid20">20,21</a>]. When the PTH is minimally elevated or within the normal range (but inappropriately normal given the patient's hypercalcemia), measurement of 24-hour urinary calcium excretion may help distinguish PHPT from FHH  (<a class="graphic graphic_algorithm graphicRef138634" href="/z/d/graphic/138634.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138635" data-inline-graphics="138635" href="/z/d/graphic/138635.html" rel="external">algorithm 2</a>) (see <a class="local">'24-hour urinary calcium'</a> below). We do not favor the use of the terms "normohormonal" or "euparathyroid" hyperparathyroidism, as they suggest a clinical distinction based upon a false dichotomy. Anyone with high calcium and a nonsuppressed PTH level has an inappropriate excess of PTH and should be considered to have hypercalcemic PHPT or FHH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTH at or below the lower end of normal range</strong> – When PTH is below or in the lower end of the normal range, non-PTH-mediated causes of hypercalcemia should be investigated  (<a class="graphic graphic_algorithm graphicRef138634" href="/z/d/graphic/138634.html" rel="external">algorithm 1</a>). Occasionally, a patient with proven PHPT has a serum intact PTH concentration in the lower half of the normal range [<a href="#rid22">22</a>] and, very rarely, one that is undetectable [<a href="#rid23">23</a>]. In the latter report, the patient had a biologically active PTH fragment, which was undetectable with the intact PTH assay. (See  <a class="medical medical_review" href="/z/d/html/2055.html" rel="external">"Parathyroid hormone assays and their clinical use", section on 'PTH fragments'</a>.)</p><p></p><p class="headingAnchor" id="H3564970"><span class="h2">24-hour urinary calcium</span><span class="headingEndMark"> — </span>Measurement of 24-hour urinary calcium excretion is not always required for the diagnosis of PHPT, but it is routinely measured in patients with asymptomatic PHPT in order to assess the risk of kidney complications (when urine calcium is high) and thus determine subsequent management (see <a class="local">'Additional evaluation to determine management'</a> below). For patients with hypercalcemia and PTH that is only minimally elevated or inappropriately normal given the patient's hypercalcemia, the 24-hour urinary calcium may also help to distinguish PHPT from FHH  (<a class="graphic graphic_algorithm graphicRef138635" href="/z/d/graphic/138635.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 40 percent of patients with PHPT are hypercalciuric, and most of the remaining patients have normal values [<a href="#rid24">24</a>]. An elevated urinary calcium concentration (&gt;200 to 300 mg/day) suggests underlying PHPT rather than FHH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If calcium excretion is &lt;200 mg/day (5.0 mmol/day), FHH or PHPT with concomitant vitamin D deficiency is possible. Lower urinary calcium values may also be seen in patients with PHPT whose calcium intake is extremely low  (<a class="graphic graphic_algorithm graphicRef138635" href="/z/d/graphic/138635.html" rel="external">algorithm 2</a>). (See <a class="local">'Serum 25-hydroxyvitamin D'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 75 percent of affected persons with FHH excrete less than 100 mg of calcium in urine daily [<a href="#rid25">25</a>]. (See <a class="local">'Familial hypocalciuric hypercalcemia'</a> below.)</p><p></p><p>A calcium/creatinine (Ca/Cr) clearance ratio, which is equivalent to the fractional excretion of calcium, may also be helpful. This ratio is calculated from 24-hour urinary calcium and creatinine and total serum calcium and creatinine concentrations using the following formula:</p><div class="formulaContainer"><div class="formula"><p>  Ca/Cr clearance ratio  =  [24-hour urine Ca  x  serum Cr]  ÷  [serum Ca  x  24-hour urine Cr]</p></div></div><p>The data establishing the value of the Ca/Cr clearance ratio in differentiating FHH from PHPT are based primarily on 24-hour urine collections. Insufficient data are available to prove that Ca/Cr ratios calculated from spot urines are equivalent to those determined from 24-hour urines.</p><p>A value below 0.01 in a vitamin D-replete individual is highly suggestive of FHH rather than PHPT (ratio usually &gt;0.02). However, up to 10 percent of individuals with FHH can have Ca/Cr clearance ratios &gt;0.02, and up to 20 percent of those with PHPT can have ratios &lt;0.01 [<a href="#rid25">25</a>]. In an analysis of five large studies combining 165 patients with FHH and 197 patients with PHPT, a Ca/Cr clearance ratio &lt;0.01 had a sensitivity for FHH of 85 percent, a specificity of 88 percent, and a positive predictive value of 85 percent; a value &gt;0.02 essentially excluded FHH [<a href="#rid26">26-28</a>]. In a subsequent case-control study of 250 patients with surgically proven PHPT and 19 patients with genetically proven FHH, the median Ca/Cr clearance ratios were 0.02 and 0.01, respectively [<a href="#rid29">29</a>]. Using a threshold of &lt;0.02, the specificity for FHH was 93 percent.</p><p>Many individuals (approximately 40 percent) with PHPT and with FHH have Ca/Cr clearance ratios between 0.01 and 0.02 [<a href="#rid25">25,29-32</a>]. Due to the difficulty of differentiating FHH from vitamin D-replete PHPT when the Ca/Cr clearance ratio is between 0.01 and 0.02, some have suggested genetic testing for FHH, where available, for such individuals. [<a href="#rid13">13,25,28,33</a>]. Genetic testing for FHH is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/838.html" rel="external">"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia", section on 'Distinction from primary hyperparathyroidism'</a>.)</p><p>The role of genetic testing in hereditary PHPT is reviewed below. (See <a class="local">'Role of genetic testing'</a> below.)</p><p class="headingAnchor" id="H3565832"><span class="h2">Serum 25-hydroxyvitamin D</span><span class="headingEndMark"> — </span>Measurement of vitamin D metabolites may be useful to distinguish PHPT from other conditions in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Differentiation of FHH from mild PHPT with concomitant vitamin D deficiency in individuals with elevated serum PTH and calcium but with normal or low 24-hour urinary calcium excretion  (<a class="graphic graphic_algorithm graphicRef138635" href="/z/d/graphic/138635.html" rel="external">algorithm 2</a>). To do so, we typically measure 25-hydroxyvitamin D (25[OH]D). In patients with underlying PHPT, urinary calcium excretion increases with vitamin D repletion, thereby distinguishing it from FHH. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Concomitant vitamin D deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Differentiation of secondary hyperparathyroidism due to vitamin D deficiency from normocalcemic PHPT in patients with elevated PTH and normal serum calcium concentrations. To do so, we typically measure 25(OH)D, which is low in secondary hyperparathyroidism and normal in normocalcemic PHPT.</p><p></p><p>Sometimes patients with presumed secondary hyperparathyroidism actually have PHPT with concomitant vitamin D deficiency. In these patients, the diagnosis of mild PHPT is obscured by vitamin D deficiency due to poor dietary intake of vitamin D or sunlight exposure and may not be recognized until vitamin D is repleted and hypercalcemia and/or hypercalciuria develop. PHPT with coexisting vitamin D deficiency may be suspected when serum calcium concentrations are in the upper half of the normal range and urinary calcium concentration is normal, despite vitamin D deficiency.</p><p>Individuals with normocalcemic PHPT and low 25(OH)D concentrations may be repleted with vitamin D. However, vitamin D replacement should be provided cautiously in those with suspected concurrent PHPT, in particular in those with a urinary calcium that is in the high-normal range, as worsening hypercalcemia and hypercalciuria may develop. In contrast, serum and urinary calcium remain normal and PTH normalizes after vitamin D repletion in individuals with vitamin D deficiency-induced secondary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Concomitant vitamin D deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Coexisting primary hyperparathyroidism'</a>.)</p><p>Patients with PHPT convert more 25(OH)D (calcidiol) to 1,25 dihydroxyvitamin D (calcitriol) than normal individuals. Serum concentrations of 1,25 dihydroxyvitamin D may therefore be at upper limits of normal or elevated [<a href="#rid34">34,35</a>]. An elevated value is not specific for diagnosis, and measurement of 1,25-dihydroxyvitamin D is not generally needed to confirm the diagnosis.</p><p class="headingAnchor" id="H3566026"><span class="h2">Role of genetic testing</span><span class="headingEndMark"> — </span>The majority of patients with PHPT do not require genetic testing. Due to the difficulty of differentiating FHH from vitamin D-replete PHPT when the Ca/Cr clearance ratio is between 0.01 and 0.02, some experts have suggested calcium-sensing receptor (<em>CaSR</em>) mutation analysis for such individuals. (See <a class="local">'Familial hypocalciuric hypercalcemia'</a> below and  <a class="medical medical_review" href="/z/d/html/838.html" rel="external">"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia", section on 'Distinction from primary hyperparathyroidism'</a>.)</p><p>Genetic testing, where available, can also be performed in selected patients in whom a familial form of PHPT is suspected, including young patients (&lt;30 years) and patients with a family history of PHPT, atypical parathyroid adenoma, or clinical findings suspicious for syndromic PHPT, such as multiple endocrine neoplasia (MEN) type 1, MEN2A, or hyperparathyroidism jaw tumor syndrome [<a href="#rid13">13</a>]. Some, but not all, experts also recommend genetic testing in patients with multigland disease [<a href="#rid36">36</a>]. Whether genetic testing alters management or treatment outcomes in patients with multigland disease remains uncertain [<a href="#rid1">1</a>]. Approximately 10 percent of patients with PHPT will have a mutation in 1 of 11 genes [<a href="#rid2">2,13,37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Genetic testing'</a>.)</p><p>Abnormalities in key growth-controlling genes, protooncogenes, or tumor suppressor genes underlie the development of parathyroid tumors, which may occur sporadically or in familial patterns. The underlying genetic abnormalities include gain-of-function changes in genes such as cyclin D1/<em>PRAD1</em> for sporadic tumors and <em>RET</em> for familial tumors, or loss-of-function mutations in genes such as <em>MEN1</em> or <em>HRPT2</em> for sporadic and familial tumors. (See  <a class="medical medical_review" href="/z/d/html/2038.html" rel="external">"Primary hyperparathyroidism: Pathogenesis and etiology", section on 'Genetic or chromosomal defects'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Although the most common clinical presentation of primary hyperparathyroidism (PHPT) is asymptomatic hypercalcemia with an elevated or high-normal intact parathyroid hormone (PTH) concentration, the presentation may be atypical. Atypical presentations include a spectrum of disturbances in calcium homeostasis, ranging from symptomatic severe hypercalcemia (parathyroid crisis) to normocalcemic PHPT. Laboratory testing often can distinguish atypical presentations of PHPT from other diseases, such as malignancy, familial hypocalciuric hypercalcemia (FHH), and secondary hyperparathyroidism  (<a class="graphic graphic_table graphicRef71910" href="/z/d/graphic/71910.html" rel="external">table 3</a>).</p><p>In PHPT and FHH, the calcium and PTH levels are usually simultaneously elevated. Careful review of the patient's prior serum calcium levels and family history may help differentiate PHPT from FHH. Non-parathyroid-mediated causes of hypercalcemia  (<a class="graphic graphic_table graphicRef71910" href="/z/d/graphic/71910.html" rel="external">table 3</a>), including milk-alkali syndrome, granulomatous disease, and hypervitaminosis D, are associated with suppressed rather than elevated PTH concentrations. They are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>PHPT and malignancy are the most common causes of hypercalcemia, accounting for more than 90 percent of cases  (<a class="graphic graphic_table graphicRef66865" href="/z/d/graphic/66865.html" rel="external">table 1</a>). It is usually not difficult to differentiate between them. Malignancy is often evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy have higher calcium concentrations and are more symptomatic from hypercalcemia than individuals with PHPT. (See  <a class="medical medical_review" href="/z/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms"</a>.)</p><p>However, it may be difficult to differentiate the two problems clinically when the presentation is less typical. As an example, some patients with occult malignancy may present with mild hypercalcemia. Alternatively, patients with hyperparathyroidism can occasionally have acute onset of severe, symptomatic hypercalcemia (parathyroid crisis). In these cases, measurement of intact PTH will usually distinguish the two diseases. Intact PTH concentrations are generally undetectable or very low in hypercalcemia of malignancy and are elevated or high-normal in PHPT  (<a class="graphic graphic_table graphicRef71910" href="/z/d/graphic/71910.html" rel="external">table 3</a>). It is uncommon for patients with hypercalcemia of malignancy to have elevated PTH levels, but this finding may occur rarely in individuals with hypercalcemia of malignancy and concomitant PHPT or in individuals with PTH-secreting tumors, which are also rare. (See  <a class="medical medical_review" href="/z/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms", section on 'Coexisting primary hyperparathyroidism'</a> and  <a class="medical medical_review" href="/z/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms", section on 'Ectopic PTH secretion'</a>.)</p><p>Patients with parathyroid carcinomas have severe hypercalcemia and PTH levels in the hundreds to thousands pg/mL range. (See  <a class="medical medical_review" href="/z/d/html/2042.html" rel="external">"Parathyroid carcinoma"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Familial hypocalciuric hypercalcemia</span><span class="headingEndMark"> — </span>FHH is an autosomal dominant disorder characterized by longstanding, mild hypercalcemia; normal or mildly elevated PTH levels; and low urinary calcium excretion. In most cases, it is due to an inactivating mutation in the calcium-sensing receptor in the parathyroid glands and the kidneys; this form of FHH is now called FHH1 [<a href="#rid26">26</a>]. A family history of hypercalcemia, especially in young children, and the absence of symptoms and signs of hypercalcemia are characteristic of this disorder. (See  <a class="medical medical_review" href="/z/d/html/838.html" rel="external">"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia", section on 'Familial hypocalciuric hypercalcemia'</a>.)</p><p>Approximately 15 to 20 percent of patients with FHH may have a mildly elevated PTH concentration [<a href="#rid26">26,27,39,40</a>]. In these individuals, it may be difficult to distinguish asymptomatic PHPT from FHH. It is important to make this distinction, however, because FHH is a benign inherited condition that typically does not require parathyroidectomy and will not be cured by it  (<a class="graphic graphic_algorithm graphicRef138635" href="/z/d/graphic/138635.html" rel="external">algorithm 2</a>).</p><p>The major feature that distinguishes FHH from PHPT is a low urine calcium excretion and calcium/creatinine (Ca/Cr) clearance ratio  (<a class="graphic graphic_table graphicRef71910" href="/z/d/graphic/71910.html" rel="external">table 3</a>). In contrast, in the absence of hypovitaminosis D, most patients with PHPT have either normal or elevated urinary calcium excretion (see <a class="local">'24-hour urinary calcium'</a> above). Because the calcium-sensing receptor is a cation receptor, urinary magnesium excretion parallels calcium excretion and is therefore low in FHH, in contrast with PHPT. Measurement of urinary magnesium is not, however, recommended in the evaluation of PHPT or FHH. (See  <a class="medical medical_review" href="/z/d/html/838.html" rel="external">"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia", section on 'Distinction from primary hyperparathyroidism'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Two drugs deserve special consideration when evaluating a patient for hyperparathyroidism: thiazide diuretics and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiazides</strong> – Thiazide diuretics, including <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">chlorthalidone</a>, reduce urinary calcium excretion and therefore can cause mild hypercalcemia (up to 11.5 mg/dL [2.9 mmol/L]) (see  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a>). In addition, some patients with hyperparathyroidism may be prescribed thiazides, which may elevate the serum calcium further and thereby unmask the hyperparathyroidism. Following discontinuation of the drug, these individuals remain hypercalcemic, although perhaps less so, and are found to have surgically proven hyperparathyroidism. Thus, if a patient taking a thiazide is found to be hypercalcemic, the drug should be withdrawn, if possible, and calcium and PTH assessed three months later. Persistent hypercalcemia (with elevated or high-normal PTH) after drug withdrawal suggests that the thiazide has unmasked PHPT. (See  <a class="medical medical_review" href="/z/d/html/2038.html" rel="external">"Primary hyperparathyroidism: Pathogenesis and etiology", section on 'Thiazide therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong> – <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> decreases parathyroid gland sensitivity to calcium, shifting the calcium-PTH curve to the right  (<a class="graphic graphic_figure graphicRef66597" href="/z/d/graphic/66597.html" rel="external">figure 2</a>). Lithium may also reduce urinary calcium excretion. Lithium is thought to affect calcium-PTH dynamics through an action downstream of the calcium-sensing receptor, but the exact locus is still unknown. Some patients taking lithium develop hypercalcemia and hypocalciuria, and a subset of these individuals have high serum PTH concentrations. If the lithium can be stopped without exacerbating the psychiatric condition, the hypercalcemia may resolve. Following discontinuation, the serum calcium concentration is more likely to normalize if the duration of lithium use had been relatively short (eg, less than a few years), but less likely if it had been longer (eg, more than 10 years). (See  <a class="medical medical_review" href="/z/d/html/2038.html" rel="external">"Primary hyperparathyroidism: Pathogenesis and etiology", section on 'Lithium therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2050.html" rel="external">"Parathyroid hormone secretion and action", section on 'Lithium and PTH secretion'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Secondary hyperparathyroidism</span><span class="headingEndMark"> — </span>Occasionally, patients with PHPT have consistently normal total and ionized calcium concentrations (normocalcemic PHPT). These patients typically come to medical attention in the setting of an evaluation for low bone mineral density (BMD). In these cases, it may be difficult to distinguish secondary hyperparathyroidism from early PHPT because the biochemical findings may be similar.</p><p>Secondary hyperparathyroidism occurs when the parathyroid gland appropriately responds to a reduced level of extracellular calcium. PTH concentrations rise, and calcium is mobilized by increasing intestinal absorption (via increase in calcitriol) and by increasing bone resorption. Thus, it is characterized biochemically by elevated PTH and normal or low serum calcium concentrations. (See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>.)</p><p>Secondary hyperparathyroidism may occur in patients with impaired kidney function and consequent impairment in calcitriol (1,25 dihydroxyvitamin D) production, as well as in individuals with inadequate calcium intake or absorption, as can occur with vitamin D deficiency or with gastrointestinal diseases causing malabsorption  (<a class="graphic graphic_table graphicRef73157" href="/z/d/graphic/73157.html" rel="external">table 2</a>). Assessment of kidney function (serum creatinine), vitamin D status (25-hydroxyvitamin D [25(OH)D]), and calcium sufficiency (urinary calcium excretion) may help differentiate normocalcemic primary and secondary hyperparathyroidism. Further assessment and work-up for specific gastrointestinal disorders is generally undertaken only when the clinical suspicion is high. It is important to rule out causes of secondary hyperparathyroidism before making the diagnosis of normocalcemic PHPT.</p><p>Some patients may have more than one condition leading to increased PTH secretion. Coexisting PHPT and vitamin D deficiency is not uncommon. When this occurs, the serum calcium level in the patient with PHPT may be reduced (into the normal range in some cases) due to vitamin D deficiency. Repletion of vitamin D in these patients will unmask their hypercalcemia. (See <a class="local">'Serum vitamin D'</a> below and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Coexisting primary hyperparathyroidism'</a>.)</p><p class="headingAnchor" id="H3565081"><span class="h1">ADDITIONAL EVALUATION TO DETERMINE MANAGEMENT</span><span class="headingEndMark"> — </span>For patients diagnosed with asymptomatic primary hyperparathyroidism (PHPT), additional evaluation is necessary to make subsequent management decisions. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management"</a>.)</p><p>Although patients with symptomatic PHPT should have parathyroid surgery, the widespread identification of asymptomatic individuals raises the question of need for and timing of surgical intervention in this population. In order to make management recommendations for patients with asymptomatic PHPT, we measure:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary calcium excretion (if not previously measured)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum 25-hydroxyvitamin D (25[OH]D) (if not previously measured)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine and estimated glomerular filtration rate (eGFR) to assess for impaired kidney function</p><p class="bulletIndent1"><span class="glyph">●</span>Bone mineral density (BMD) to assess for osteoporosis</p><p></p><p>In patients who do not meet surgical criteria based on the tests above, additional imaging may detect subclinical manifestations of PHPT in bone and kidney and thereby further inform a decision about surgery. (See <a class="local">'Vertebral and kidney imaging studies'</a> below.)</p><p>Urinary stone risk profile is also reasonable in patients with hypercalciuria or kidney stones to inform additional intervention, including possible parathyroid surgery. (See <a class="local">'Biochemical evaluation for risk factors for kidney stone formation'</a> below.)</p><p class="headingAnchor" id="H3565110"><span class="h2">Urinary calcium excretion</span><span class="headingEndMark"> — </span>In asymptomatic patients, the urinary calcium excretion is helpful to assess the risk of kidney complications (when urine calcium is high) and thus determine subsequent management. The Fifth International Workshop on Asymptomatic Primary Hyperparathyroidism guidelines recommend surgical intervention as opposed to observation for asymptomatic patients with a 24-hour urinary calcium excretion &gt;250 mg/24 hours in women and &gt;300 mg/24 hours in men [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.)</p><p class="headingAnchor" id="H3565203"><span class="h2">Serum vitamin D</span><span class="headingEndMark"> — </span>We measure serum 25(OH)D in all patients with suspected or diagnosed PHPT. Measurement of 25(OH)D is important to identify patients with both PHPT and vitamin D deficiency, who require vitamin D repletion. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Concomitant vitamin D deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Coexisting primary hyperparathyroidism'</a>.)</p><p>Due to the significant prevalence of vitamin D insufficiency in individuals with PHPT, the Fifth International Workshop on Asymptomatic Primary Hyperparathyroidism recommends measuring 25(OH)D in all patients with the disease and repleting those with low levels (defined as ≤30 ng/mL [75 nmol/L]) to achieve levels between 30 and 50 ng/mL (75 to 125 nmol/L) prior to making any management decisions [<a href="#rid1">1</a>]. In some cases, the decision regarding surgery will be clear despite the low vitamin D level. In such patients, it is still advisable to replete vitamin D if this can be done safely, in order to mitigate postoperative hypocalcemia.</p><p class="headingAnchor" id="H937858"><span class="h2">Serum creatinine</span><span class="headingEndMark"> — </span>The serum creatinine concentration provides information about kidney function, which can be diminished by hypercalcemia. Rather than using serum creatinine alone, the eGFR can be estimated in patients with a stable serum creatinine concentration. (See  <a class="medical medical_review" href="/z/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function", section on 'Estimation of GFR'</a>.)</p><p>An eGFR of 60 mL/min/1.73 m<sup>2</sup> is generally regarded as the threshold of chronic kidney disease for deciding which asymptomatic individuals with PHPT may benefit from early surgical treatment [<a href="#rid1">1,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.) </p><p class="headingAnchor" id="H937956"><span class="h2">Bone mineral density</span><span class="headingEndMark"> — </span>Patients with hyperparathyroidism may have decreased BMD, in particular at more cortical sites (forearm and hip) as compared with more trabecular (cancellous) sites (spine). Although measurement of BMD is not required for the diagnosis of PHPT, it is an essential part of the management of the disease. In all patients with PHPT, including those with normocalcemic PHPT, BMD must be measured at the spine, hip, and distal one-third forearm sites [<a href="#rid41">41</a>]. The degree of bone loss is reflective of the severity of hyperparathyroidism and is useful for making recommendations for parathyroid surgery or observation with monitoring in asymptomatic patients. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Asymptomatic'</a> and  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Subclinical bone disease'</a>.)</p><p class="headingAnchor" id="H3163424640"><span class="h2">Vertebral and kidney imaging studies</span><span class="headingEndMark"> — </span>If initial evaluation does not demonstrate any indications for surgery, additional imaging may detect subclinical manifestations of PHPT in bone and kidney [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H17670838"><span class="h3">Vertebral imaging</span><span class="headingEndMark"> — </span>In patients without other indications for surgery, most UpToDate contributors obtain imaging to assess for asymptomatic vertebral fracture. However, some UpToDate contributors limit imaging for vertebral fracture to patients with clinical findings that suggest prior fracture (eg, kyphosis, height loss).</p><p>Vertebral imaging can be performed with plain radiographs or with vertebral fracture assessment (VFA) by dual-energy x-ray absorptiometry (DXA). The latter can be done at the time of BMD testing, at greater patient convenience, less cost, and lower radiation exposure than conventional radiography of the spine. If a vertebral fracture is present by radiograph or VFA, parathyroidectomy is recommended [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry", section on 'Vertebral fracture assessment'</a> and  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.)</p><p>The Fifth International Workshop guidelines advocate for vertebral imaging in all patients who do not otherwise meet criteria for parathyroidectomy [<a href="#rid1">1</a>]. This guidance is based on expert opinion and observational evidence demonstrating underdiagnosis of vertebral compression fractures in all populations and an increased risk of asymptomatic vertebral fractures in patients with PHPT. Patients with subclinical, idiopathic vertebral compression fractures are regarded as having osteoporosis, independent of BMD findings. (See  <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations", section on 'Skeletal'</a>.)</p><p class="headingAnchor" id="H3282056009"><span class="h3">Kidney imaging</span><span class="headingEndMark"> — </span>In patients without other indications for surgery, some UpToDate contributors perform kidney imaging to assess for nephrocalcinosis or a clinically silent kidney stone. However, other UpToDate contributors do not obtain additional kidney imaging in asymptomatic patients. Imaging studies can include plain radiograph, ultrasound, or computed tomography (CT) scan; ultrasound is typically used most commonly. Imaging evidence of nephrocalcinosis or kidney stone(s) demonstrates end-organ damage and therefore meets criteria for surgical intervention [<a href="#rid1">1</a>].</p><p>The Fifth International Workshop guidelines advocate for kidney imaging in all patients who do not otherwise meet criteria for parathyroidectomy [<a href="#rid1">1</a>]. This guidance is based on expert opinion and observational evidence demonstrating clinically silent kidney stones in 7 to 22 percent of patients with asymptomatic PHPT, including individuals with mild hypercalcemia or normocalcemic disease [<a href="#rid42">42-46</a>]. (See  <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations", section on 'Nephrolithiasis'</a> and  <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations", section on 'Normocalcemic primary hyperparathyroidism'</a>.)</p><p class="headingAnchor" id="H2603978737"><span class="h2">Biochemical evaluation for risk factors for kidney stone formation</span><span class="headingEndMark"> — </span>For patients with hypercalciuria or a history of kidney stones, a stone risk profile is reasonable to identify factors contributing to stone risk that may be modifiable through lifestyle measures alone (eg, low urine volume, high urinary protein or sodium excretion). Stone risk profile may identify other risk factors that would not be modified by parathyroidectomy and therefore require alternative intervention (eg, low urine pH suggesting risk of uric acid stones). (See  <a class="medical medical_review" href="/z/d/html/7377.html" rel="external">"Kidney stones in adults: Evaluation of the patient with established stone disease", section on '24-hour urine collections'</a> and  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.) </p><p>In patients without hypercalciuria or kidney stones, a stone risk profile is not recommended [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H538507"><span class="h2">Other tests</span><span class="headingEndMark"> — </span>Other tests that may provide useful clinical information include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum phosphorus</strong> – The serum phosphorus concentration may be decreased but typically is in the lower range of normal. Some patients have mild hyperchloremic acidosis. (See  <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Markers of bone turnover</strong> – Biochemical markers of bone turnover (collagen crosslinks, osteocalcin, bone-specific alkaline phosphatase) are often at the upper end of normal or mildly elevated in asymptomatic PHPT (see  <a class="medical medical_review" href="/z/d/html/2047.html" rel="external">"Bone physiology and biochemical markers of bone turnover"</a>). In those with more severe disease, they are typically high. They are only occasionally helpful in the management of hyperparathyroidism and should not be routinely measured [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Localization studies</span><span class="headingEndMark"> — </span>The diagnosis of PHPT is established by appropriate biochemical testing. Localization studies with ultrasonography, technetium-99m sestamibi, CT, or magnetic resonance imaging (MRI) scanning should <strong>not</strong> be used to establish the diagnosis of PHPT or to determine management. Localization studies should be performed only after a decision for surgery has been made [<a href="#rid1">1</a>]. Their utility is questionable when bilateral neck exploration is planned. However, they are commonly used now, along with intraoperative parathyroid hormone (PTH) monitoring, to facilitate unilateral exploration and minimally invasive surgery in those with probable single gland disease. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism"</a>.)</p><p class="headingAnchor" id="H1370415010"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114494.html" rel="external">"Society guideline links: Primary hyperparathyroidism"</a>.)</p><p class="headingAnchor" id="H16095866"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16549.html" rel="external">"Patient education: Primary hyperparathyroidism (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/2164.html" rel="external">"Patient education: Primary hyperparathyroidism (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary hyperparathyroidism (PHPT)</strong> – The diagnosis of PHPT is usually first suspected because of the incidental finding of an elevated serum calcium concentration on biochemical screening tests. In addition, PHPT may be suspected in a patient with nephrolithiasis. PHPT is diagnosed by finding a frankly elevated parathyroid hormone (PTH) concentration in a patient with hypercalcemia. When the PTH is only minimally elevated, or within the normal range (but inappropriately normal given the patient's hypercalcemia), PHPT remains the most likely diagnosis, although familial hypocalciuric hypercalcemia (FHH) is possible  (<a class="graphic graphic_algorithm graphicRef138634" href="/z/d/graphic/138634.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normocalcemic PHPT</strong> – Normocalcemic PHPT is a variant of PHPT. Patients with normocalcemic PHPT typically come to medical attention in the setting of an evaluation for low bone mineral density (BMD), during which time PTH levels are drawn and found to be elevated in the absence of hypercalcemia. In such cases, BMD at cortical sites may be preferentially affected. In order to make this diagnosis, all secondary causes for hyperparathyroidism  (<a class="graphic graphic_table graphicRef73157" href="/z/d/graphic/73157.html" rel="external">table 2</a>) must be ruled out and ionized calcium levels should be normal. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Bone mineral density'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – For patients with hypercalcemia and PTH that is only minimally elevated or inappropriately normal given the patient's hypercalcemia, further evaluation is necessary to confirm the diagnosis. We measure urinary calcium excretion and 25-hydroxyvitamin D (25[OH]D) in all patients with suspected PHPT  (<a class="graphic graphic_algorithm graphicRef138635" href="/z/d/graphic/138635.html" rel="external">algorithm 2</a>). Measurement of 24-hour urine calcium excretion is helpful for distinguishing PHPT from FHH. Measurement of 25(OH)D is not only important to distinguish PHPT from other conditions, but also to identify patients with both PHPT and vitamin D deficiency, who require vitamin D repletion. (See <a class="local">'24-hour urinary calcium'</a> above and <a class="local">'Serum 25-hydroxyvitamin D'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Although the most common clinical presentation of PHPT is asymptomatic hypercalcemia with an elevated or high-normal intact PTH concentration, the presentation may be atypical. Atypical presentations include a spectrum of disturbances in calcium homeostasis, ranging from symptomatic severe hypercalcemia (parathyroid crisis) to normocalcemic PHPT. Laboratory testing often can distinguish atypical presentations of PHPT from other diseases, such as malignancy, FHH, and secondary hyperparathyroidism  (<a class="graphic graphic_table graphicRef71910" href="/z/d/graphic/71910.html" rel="external">table 3</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation to determine management</strong> – For patients diagnosed with asymptomatic PHPT, additional evaluation is necessary to make subsequent management decisions. (See <a class="local">'Additional evaluation to determine management'</a> above and  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Surgery versus nonsurgical management'</a>.)</p><p></p><p class="bulletIndent1">Although patients with symptomatic PHPT should have parathyroid surgery, the widespread identification of asymptomatic individuals raises the question of the need for and timing of surgical intervention in this population. In order to make management recommendations for patients with asymptomatic PHPT, we measure urinary calcium excretion and serum 25(OH)D (if both have not been previously measured), assess kidney function by estimated glomerular filtration rate (eGFR), and measure BMD. (See <a class="local">'Additional evaluation to determine management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vertebral and kidney imaging</strong> – In patients who do not meet surgical criteria based on the above tests, most UpToDate contributors obtain imaging of the spine to assess for asymptomatic vertebral compression fracture. Some UpToDate contributors also perform kidney imaging to assess for nephrocalcinosis or a clinically silent kidney stone. In patients with subclinical manifestations of PHPT in bone or kidney, parathyroidectomy is recommended. (See <a class="local">'Vertebral and kidney imaging studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biochemical stone risk profile</strong> – In patients with hypercalciuria or history of kidney stones, additional evaluation with a biochemical stone risk profile can help determine both the risk of kidney stones and the likelihood that risk is specifically conferred by PHPT-mediated hypercalcemia. (See <a class="local">'Biochemical evaluation for risk factors for kidney stone formation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localization tests</strong> – Localization studies with ultrasonography, technetium-99m sestamibi, CT, or MRI scanning should <strong>not</strong> be used to establish the diagnosis of PHPT or to determine management. If localization studies are performed, they should be done after a decision for surgery has been made. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res 2022; 37:2293.</a></li><li><a class="nounderline abstract_t">Minisola S, Arnold A, Belaya Z, et al. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. J Bone Miner Res 2022; 37:2315.</a></li><li><a class="nounderline abstract_t">Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92:3001.</a></li><li><a class="nounderline abstract_t">Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3580.</a></li><li><a class="nounderline abstract_t">Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013; 16:33.</a></li><li><a class="nounderline abstract_t">Crowley RK, Gittoes NJ. Elevated PTH with normal serum calcium level: a structured approach. Clin Endocrinol (Oxf) 2016; 84:809.</a></li><li><a class="nounderline abstract_t">Rosário PW, Calsolari MR. Normocalcemic Primary Hyperparathyroidism in Adults Without a History of Nephrolithiasis or Fractures: A Prospective Study. Horm Metab Res 2019; 51:243.</a></li><li><a class="nounderline abstract_t">Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017; 28:1.</a></li><li><a class="nounderline abstract_t">El-Hajj Fuleihan G, Chakhtoura M, Cipriani C, et al. Classical and Nonclassical Manifestations of Primary Hyperparathyroidism. J Bone Miner Res 2022; 37:2330.</a></li><li><a class="nounderline abstract_t">Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:2036.</a></li><li><a class="nounderline abstract_t">Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol 2018; 14:115.</a></li><li><a class="nounderline abstract_t">Glendenning P, Gutteridge DH, Retallack RW, et al. High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria. Aust N Z J Med 1998; 28:173.</a></li><li><a class="nounderline abstract_t">Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3570.</a></li><li><a class="nounderline abstract_t">Silverberg SJ, Gao P, Brown I, et al. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:4725.</a></li><li><a class="nounderline abstract_t">Boudou P, Ibrahim F, Cormier C, et al. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:6370.</a></li><li><a class="nounderline abstract_t">Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004; 50:626.</a></li><li><a class="nounderline abstract_t">Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991; 37:162.</a></li><li><a class="nounderline abstract_t">Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364.</a></li><li><a class="nounderline abstract_t">Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:351.</a></li><li><a class="nounderline abstract_t">Fuleihan GE, Gundberg CM, Gleason R, et al. Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 1994; 79:1642.</a></li><li><a class="nounderline abstract_t">Grant FD, Conlin PR, Brown EM. Rate and concentration dependence of parathyroid hormone dynamics during stepwise changes in serum ionized calcium in normal humans. J Clin Endocrinol Metab 1990; 71:370.</a></li><li><a class="nounderline abstract_t">Hollenberg AN, Arnold A. Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am J Med 1991; 91:547.</a></li><li><a class="nounderline abstract_t">Au AY, McDonald K, Gill A, et al. PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med 2008; 359:1184.</a></li><li><a class="nounderline abstract_t">Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990; 89:327.</a></li><li class="breakAll">El-Hajj Fuleihan G, Brown EM. Familial Hypocalciuric Hypercalcemia and Neonatal Severe Hyperparathyroidism. In: The Parathyroids, 3rd ed, Bilezikian JP, Marcus R, Levine MA, et al (Eds), Elsevier, London 2014. p.365.</li><li><a class="nounderline abstract_t">Fuleihan Gel-H. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res 2002; 17 Suppl 2:N51.</a></li><li><a class="nounderline abstract_t">Marx SJ, Stock JL, Attie MF, et al. Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 1980; 92:351.</a></li><li><a class="nounderline abstract_t">Marx SJ. Letter to the editor: Distinguishing typical primary hyperparathyroidism from familial hypocalciuric hypercalcemia by using an index of urinary calcium. J Clin Endocrinol Metab 2015; 100:L29.</a></li><li><a class="nounderline abstract_t">Arshad MF, McAllister J, Merchant A, et al. Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): which test performs best? Postgrad Med J 2021; 97:577.</a></li><li><a class="nounderline abstract_t">Moore EC, Berber E, Jin J, et al. CALCIUM CREATININE CLEARANCE RATIO IS NOT HELPFUL IN DIFFERENTIATING PRIMARY HYPERPARATHYROIDISM FROM FAMILIAL HERPERCALCEMIC HYPOCALCIURIA: A STUDY OF 1000 PATIENTS. Endocr Pract 2018.</a></li><li><a class="nounderline abstract_t">Vargas-Poussou R, Mansour-Hendili L, Baron S, et al. Familial Hypocalciuric Hypercalcemia Types 1 and 3 and Primary Hyperparathyroidism: Similarities and Differences. J Clin Endocrinol Metab 2016; 101:2185.</a></li><li><a class="nounderline abstract_t">Marx SJ. Familial Hypocalciuric Hypercalcemia as an Atypical Form of Primary Hyperparathyroidism. J Bone Miner Res 2018; 33:27.</a></li><li><a class="nounderline abstract_t">Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) 2008; 69:713.</a></li><li><a class="nounderline abstract_t">Broadus AE, Horst RL, Lang R, et al. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med 1980; 302:421.</a></li><li><a class="nounderline abstract_t">Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341:1249.</a></li><li><a class="nounderline abstract_t">Jha S, Simonds WF. Molecular and Clinical Spectrum of Primary Hyperparathyroidism. Endocr Rev 2023; 44:779.</a></li><li><a class="nounderline abstract_t">Marini F, Cianferotti L, Giusti F, Brandi ML. Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update. Clin Cases Miner Bone Metab 2017; 14:60.</a></li><li><a class="nounderline abstract_t">Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer 2019; 26:R441.</a></li><li class="breakAll">El-Hajj Fuleihan G, Heath H III. Familial benign hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. In: The Parathyroids: Basic and Clinical Concepts, 2nd, Bilezikian JP, Marcus R, Levine MA (Eds), Academic Press, San Diego 2001. p.607.</li><li><a class="nounderline abstract_t">Nissen PH, Christensen SE, Heickendorff L, et al. Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population. J Clin Endocrinol Metab 2007; 92:4373.</a></li><li><a class="nounderline abstract_t">Bilezikian JP, Silverberg SJ, Bandeira F, et al. Management of Primary Hyperparathyroidism. J Bone Miner Res 2022; 37:2391.</a></li><li><a class="nounderline abstract_t">Cassibba S, Pellegrino M, Gianotti L, et al. Silent renal stones in primary hyperparathyroidism: prevalence and clinical features. Endocr Pract 2014; 20:1137.</a></li><li><a class="nounderline abstract_t">Suh JM, Cronan JJ, Monchik JM. Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 2008; 191:908.</a></li><li><a class="nounderline abstract_t">Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011; 96:2377.</a></li><li><a class="nounderline abstract_t">Tay YD, Liu M, Bandeira L, et al. Occult urolithiasis in asymptomatic primary hyperparathyroidism. Endocr Res 2018; 43:106.</a></li><li><a class="nounderline abstract_t">Misgar RA, Sehgal A, Masoodi SR, et al. A Comparison between Silent and Symptomatic Renal Stones in Primary Hyperparathyroidism. Indian J Endocrinol Metab 2019; 23:46.</a></li></ol></div><div id="topicVersionRevision">Topic 2029 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36245251" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36245271" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17536001" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162667" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374739" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Normocalcemic primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26939669" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Elevated PTH with normal serum calcium level: a structured approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30840998" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Normocalcemic Primary Hyperparathyroidism in Adults Without a History of Nephrolithiasis or Fractures: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27613721" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36245249" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Classical and Nonclassical Manifestations of Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964825" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation and management of primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28885621" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9612524" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162666" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557447" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189258" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718396" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1993319" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3608153" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19193910" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7989469" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Racial differences in parathyroid hormone dynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2380334" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rate and concentration dependence of parathyroid hormone dynamics during stepwise changes in serum ionized calcium in normal humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951417" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784115" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : PTH mutation with primary hyperparathyroidism and undetectable intact PTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2393037" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nephrolithiasis and bone involvement in primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2393037" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nephrolithiasis and bone involvement in primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412778" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Familial benign hypocalciuric hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7356229" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25658165" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Letter to the editor: Distinguishing typical primary hyperparathyroidism from familial hypocalciuric hypercalcemia by using an index of urinary calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32892159" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): which test performs best?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289313" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : CALCIUM CREATININE CLEARANCE RATIO IS NOT HELPFUL IN DIFFERENTIATING PRIMARY HYPERPARATHYROIDISM FROM FAMILIAL HERPERCALCEMIC HYPOCALCIURIA: A STUDY OF 1000 PATIENTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26963950" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Familial Hypocalciuric Hypercalcemia Types 1 and 3 and Primary Hyperparathyroidism: Similarities and Differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29115694" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Familial Hypocalciuric Hypercalcemia as an Atypical Form of Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410554" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7351950" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10528034" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36961765" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Molecular and Clinical Spectrum of Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28740527" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31085770" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31085770" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698911" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36054638" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Management of Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24936557" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Silent renal stones in primary hyperparathyroidism: prevalence and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18716127" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Primary hyperparathyroidism: is there an increased prevalence of renal stone disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21646371" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nephrolithiasis and renal calcifications in primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29400579" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Occult urolithiasis in asymptomatic primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31016152" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A Comparison between Silent and Symptomatic Renal Stones in Primary Hyperparathyroidism.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
